Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Possible Biomarkers for Cancer Immunotherapy.

Otoshi T, Nagano T, Tachihara M, Nishimura Y.

Cancers (Basel). 2019 Jul 3;11(7). pii: E935. doi: 10.3390/cancers11070935. Review.

2.

Novel cancer therapy targeting microbiome.

Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, Nishimura Y.

Onco Targets Ther. 2019 May 13;12:3619-3624. doi: 10.2147/OTT.S207546. eCollection 2019. Review.

3.

A Cross-sectional Survey of the Clinical Manifestations and Underlying Illness of Cough.

Otoshi T, Nagano T, Funada Y, Takenaka K, Nakata H, Ohnishi H, Nishiuma T, Nakajima T, Kageshita T, Tsuchiya T, Yamamoto M, Kobayashi K, Nishimura Y.

In Vivo. 2019 Mar-Apr;33(2):543-549. doi: 10.21873/invivo.11508.

4.

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.

Katsurada M, Nagano T, Tachihara M, Kiriu T, Furukawa K, Koyama K, Otoshi T, Sekiya R, Hazama D, Tamura D, Nakata K, Katsurada N, Yamamoto M, Kobayashi K, Nishimura Y.

Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180.

PMID:
30711962
5.

Influence of social determinants of health on patients with advanced lung cancer: a prospective cohort study.

Takemura T, Kataoka Y, Okazaki K, Sakurai A, Imakita T, Ikegaki S, Matsumoto H, Saito E, Takata H, Kaku S, Wada N, Shinomiya M, Otoshi T, Shimada M, Nikaido J, Iki R, Hirano K, Hirai T, Endo K, Naganuma T.

BMJ Open. 2018 Oct 21;8(10):e023152. doi: 10.1136/bmjopen-2018-023152.

6.
7.

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

Otoshi T, Kataoka Y, Ikegaki S, Saito E, Matsumoto H, Kaku S, Shimada M, Hirabayashi M.

PLoS One. 2017 Oct 2;12(10):e0185850. doi: 10.1371/journal.pone.0185850. eCollection 2017.

8.

Evaluation of discomfort and tolerability to bronchoscopy according to different sedation procedures with midazolam.

Matsumoto T, Otsuka K, Kato R, Shimizu R, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Nagata K, Otsuka K, Nakagawa A, Tomii K.

Exp Ther Med. 2015 Aug;10(2):659-664. Epub 2015 Jun 4.

9.

Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.

Fujimoto D, Shimizu R, Kato R, Sato Y, Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Anticancer Res. 2015 Nov;35(11):6261-6.

PMID:
26504060
10.

Efficacy of High-Flow Nasal Cannula Therapy in Acute Hypoxemic Respiratory Failure: Decreased Use of Mechanical Ventilation.

Nagata K, Morimoto T, Fujimoto D, Otoshi T, Nakagawa A, Otsuka K, Seo R, Atsumi T, Tomii K.

Respir Care. 2015 Oct;60(10):1390-6. doi: 10.4187/respcare.04026. Epub 2015 Jun 23.

11.

Analysis of advanced lung cancer patients diagnosed following emergency admission.

Fujimoto D, Shimizu R, Morimoto T, Kato R, Sato Y, Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Eur Respir J. 2015 Apr;45(4):1098-107. doi: 10.1183/09031936.00068114. Epub 2014 Oct 16.

12.

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66. doi: 10.1007/s00280-014-2590-x. Epub 2014 Sep 23.

PMID:
25245821
13.

Prognostic value of bronchoalveolar lavage in patients with non-HIV pneumocystis pneumonia.

Tamai K, Tachikawa R, Tomii K, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Matsumoto T, Monden K, Takeshita J, Tanaka K, Kawamura T, Otoshi T, Fujimoto D.

Intern Med. 2014;53(11):1113-7. Epub 2014 Jun 1.

14.

Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.

Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, Tamai K, Shibata Y, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Clin Exp Metastasis. 2014 Jun;31(5):543-51. doi: 10.1007/s10585-014-9648-3. Epub 2014 Mar 30.

PMID:
24682604
15.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

16.

Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.

Fujimoto D, Tomii K, Otoshi T, Kawamura T, Tamai K, Takeshita J, Tanaka K, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Hata A, Tachikawa R, Otsuka K, Hamakawa H, Katakami N, Takahashi Y, Imai Y.

Lung Cancer. 2013 May;80(2):159-64. doi: 10.1016/j.lungcan.2013.01.017. Epub 2013 Feb 16.

PMID:
23419507

Supplemental Content

Loading ...
Support Center